Bausch + Lomb (NYSE:BLCO) continued to trade lower on Friday as Wells Fargo downgraded the Canadian eyecare firm in reaction ...

Bausch + Lomb announced a recall of its enVista IOLs, including Aspire, Envy, and certain lots of monofocal lenses, due to reports of toxic anterior segment syndrome. Wells Fargo highlighted that ...

Wells Fargo downgraded Bausch + Lomb (BLCO) to Equal Weight from Overweight with a price target of $15, down from $24.Light Up your Portfolio ...

Wells Fargo downgraded Bausch + Lomb (BLCO) to Equal Weight from Overweight with a price target of $15, down from $24. The company’s announced ...

The latest price target for Bausch & Lomb (NYSE:BLCO) was reported by RBC Capital on April 4, 2025. The analyst firm set a price target for $17.00 expecting BLCO to rise to within 12 months (a ...

Bausch + Lomb announced a recall of its enVista IOLs, including Aspire, Envy, and certain lots of monofocal lenses, due to ...

Bausch + Lomb (NYSE:BLCO) continued to trade lower on Friday as Wells Fargo downgraded the Canadian eyecare firm in reaction to a voluntary recall of several brands of its enVista line of ...

Investing.com -- Wells Fargo downgraded Bausch + Lomb Corp to Equal Weight from Overweight on uncertainty from the voluntary recall of its enVista intraocular lenses (IOLs), which is expected to ...